Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which
MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients with HER2- Tumors by Tissue Analysis San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) and
Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team SAN DIEGO / — Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept’s Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr.
Data for the detection and monitoring of key predictive biomarkers for patients with newly diagnosed or progressing metastatic lung cancer on therapy to be presented at the Association for Molecular Pathology Annual Meeting SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc.
Stockholders requested to vote FOR Proposal SAN DIEGO , July 16, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer,
Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help
Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant allele frequency as low as 0.01% SAN DIEGO , Aug. 22, 2019 /PRNewswire/ -- Biocept, Inc .
Study data further support the clinical utility and validation of Biocept's CTC and ctDNA tests to profile and monitor biomarker status in patients diagnosed with cancer
Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)
Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , July 31, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
